Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Net Income (Common)
Tibet Rhodiola Pharmaceutical Holding Co
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Net Income (Common)
¥800.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
30%
|
CAGR 10-Years
40%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Net Income (Common)
¥8.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Net Income (Common)
¥3.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Net Income (Common)
¥2.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Net Income (Common)
¥2.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Net Income (Common)
¥2.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common)?
Net Income (Common)
800.9m
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common) amounts to 800.9m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
40%
Over the last year, the Net Income (Common) growth was 117%. The average annual Net Income (Common) growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 24% over the past three years , 30% over the past five years , and 40% over the past ten years .